Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,865,550
  • Shares Outstanding, K 298,806
  • Annual Sales, $ 399,360 K
  • Annual Income, $ -151,580 K
  • EBIT $ 14 M
  • EBITDA $ 24 M
  • 60-Month Beta 0.68
  • Price/Sales 7.12
  • Price/Cash Flow N/A
  • Price/Book 15.91

Options Overview Details

View History
  • Implied Volatility 34.12% ( -0.42%)
  • Historical Volatility 51.00%
  • IV Percentile 21%
  • IV Rank 25.52%
  • IV High 115.40% on 10/09/24
  • IV Low 6.26% on 10/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 24
  • Volume Avg (30-Day) 1,403
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 16,150
  • Open Int (30-Day) 38,120

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.03
  • Number of Estimates 6
  • High Estimate 0.10
  • Low Estimate -0.04
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +127.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.37 +0.67%
on 11/19/24
12.65 -25.43%
on 11/06/24
-2.58 (-21.46%)
since 10/21/24
3-Month
9.37 +0.67%
on 11/19/24
12.65 -25.43%
on 11/06/24
-2.66 (-21.98%)
since 08/21/24
52-Week
9.02 +4.58%
on 05/13/24
14.57 -35.26%
on 12/28/23
-1.33 (-12.33%)
since 11/21/23

Most Recent Stories

More News
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

Rocket Pharmaceuticals, Inc. RCKT incurred a loss of 71 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 78 cents. In the year-ago quarter, the company...

FOLD : 9.47 (-1.25%)
IMCR : 32.30 (-0.37%)
CSTL : 29.01 (+1.97%)
RCKT : 12.87 (-1.30%)
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up

Puma Biotechnology, Inc. PBYI reported third-quarter 2024 adjusted earnings of 45 cents per share, which beat the Zacks Consensus Estimate of 35 cents. In the year-ago quarter, the company had reported...

FOLD : 9.47 (-1.25%)
IMCR : 32.30 (-0.37%)
PBYI : 2.87 (+1.06%)
CSTL : 29.01 (+1.97%)
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a...

FOLD : 9.47 (-1.25%)
ESPR : 2.41 (-0.41%)
CRSP : 46.07 (-2.52%)
LSTA : 2.85 (-2.73%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 9.47 (-1.25%)
AVIR : 3.22 (+1.90%)
CRSP : 46.07 (-2.52%)
APLS : 26.67 (-2.98%)
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

Beam Therapeutics Inc. BEAM incurred a loss of $1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.22 per share...

BEAM : 23.46 (-4.21%)
FOLD : 9.47 (-1.25%)
AVIR : 3.22 (+1.90%)
CRSP : 46.07 (-2.52%)
Amicus Therapeutics: Q3 Earnings Snapshot

Amicus Therapeutics: Q3 Earnings Snapshot

FOLD : 9.47 (-1.25%)
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

FOLD : 9.47 (-1.25%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

FOLD : 9.47 (-1.25%)
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven earnings...

FOLD : 9.47 (-1.25%)
AMRN : 0.5014 (+1.42%)
ARDX : 4.98 (+1.22%)
ATNM : 1.4000 (+0.72%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 9.47 (-1.25%)
CORT : 56.10 (+0.02%)
ARDX : 4.98 (+1.22%)
ATNM : 1.4000 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is...

See More

Key Turning Points

3rd Resistance Point 10.02
2nd Resistance Point 9.85
1st Resistance Point 9.72
Last Price 9.47
1st Support Level 9.42
2nd Support Level 9.25
3rd Support Level 9.12

See More

52-Week High 14.57
Fibonacci 61.8% 12.45
Fibonacci 50% 11.80
Fibonacci 38.2% 11.14
Last Price 9.47
52-Week Low 9.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar